Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7335)	12/21/1999 9:04:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 9719

V1, Tonights news: Aurora Biosciences Announces Issuance of U.S. Patent For Novel G-Protein Technology SAN DIEGO, Dec. 21 /PRNewswire/ -- Aurora Biosciences Corporation (Nasdaq: ABSC - news) announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 6,004,808 entitled ``Promiscuous G-Protein Compositions and Their Use.' The patent is directed towards cells comprising promiscuous G-proteins such as G alpha 15, and methods for their use in drug screening. G-proteins are one of a class of proteins that couple receptors, which respond to extracellular signals such as hormones and neurotransmitters, to signal transduction pathways within the cell. Hundreds of distinct G-protein coupled receptors (GPCRs), which couple to a variety of G-protein subtypes, have been identified in the human body, and many drugs target these receptors. The promiscuous G-proteins (such as G alpha 15 and G alpha 16) constitute a class of G-proteins that functionally couple to most receptor types. By doing so, promiscuous G-proteins enable facile, effective methods for developing cell-based screens across a range of receptor types, irrespective of their degree of functional characterization. <snip>